Surrozen (SRZN) Capital Expenditures (2020 - 2026)
Surrozen (SRZN) posted quarterly Capital Expenditures of $120000.0 for Q1 2026, up 344.44% year-over-year from $27000.0 in Q1 2025, and up 103.39% quarter-over-quarter from $59000.0 in Q4 2025.
Powered by 
Analysis
Surrozen (SRZN) Capital Expenditures (2020 - 2026) Analysis & Trends
Surrozen's Capital Expenditures history runs 7 years deep, the most recent figure standing at $120000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures rose 344.44% year-over-year to $120000.0; the TTM figure through Mar 2026 stood at $221000.0 (up 662.07% YoY), while the FY2025 annual figure was $128000.0, up 1322.22% from the prior year.
- Capital Expenditures for Q1 2026 stood at $120000.0, up from $59000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $412000.0 in Q1 2022, with the low at -$426000.0 in Q3 2022.
- The 5-year median for Capital Expenditures is $27000.0 (2025), against an average of $56923.1.
- The sharpest annual moves came in 2022 and 2025: Capital Expenditures plunged 117.35% in 2022, then jumped 2850.0% in 2025.
- Surrozen's Capital Expenditures stood at $76000.0 in 2022, then advanced by 9.21% to $83000.0 in 2023, then plunged by 97.59% to $2000.0 in 2024, then surged by 2850.0% to $59000.0 in 2025, then soared by 103.39% to $120000.0 in 2026.
- Business Quant data shows SRZN's Capital Expenditures at $120000.0 in Q1 2026, $59000.0 in Q4 2025, and $24000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Surrozen | 263.35 Mn | 263.35 Mn | - | 19,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 19,000.00 |
| Mar 31, 2026 | 120,000.00 |
| Dec 31, 2025 | 211,000.00 |
| Sep 30, 2025 | 24,000.00 |
| Jun 30, 2025 | 18,000.00 |
| Mar 31, 2025 | 27,000.00 |
| Dec 31, 2024 | 19,000.00 |
| Mar 31, 2024 | 7,000.00 |
| Jun 30, 2023 | 83,000.00 |
| Mar 31, 2023 | 315,000.00 |
| Dec 31, 2022 | 148,000.00 |
| Sep 30, 2022 | 145,000.00 |
| Jun 30, 2022 | 23,000.00 |
| Mar 31, 2022 | 412,000.00 |
| Dec 31, 2021 | 324,000.00 |
| Sep 30, 2021 | 541,000.00 |
| Jun 30, 2021 | 61,000.00 |
| Mar 31, 2021 | 343,000.00 |
| Dec 31, 2020 | 460,000.00 |
| Sep 30, 2020 | 30,000.00 |